3Rothstein R. Safety profiles of leading nonsteroidal anti-inflamatory drugs [J]. Am J Med, 1998, 105(5A):39s-43s.
4Geisslinger G, schustrer O, Stock KP,et al. Pharmacokinetics of S(+)-and R(-)-ibuprofen in rheumatoid arthritis [J]. Eur J Clin Pharmacol, 1990, 38(5):493-497.
5Cappell MS, Schema JR. Diagnosis and treatment of nosteroidal anti-inflammatory drug-associated upper gastrointestinal toxicity [J]. Gastroenterol Clin North Am, 2000, 29(1):97-125.
6Rosser RG.Treatment of Proctosigmoiditis[C].American Proctologic Society,1971.
7Farthing MJ,Rutland MD,Clark ML.Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis[J].Br Med J,1979,2(6194):822-824.
8Tromm A,Mollmann H,Barth J,et al.Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients[J].J Clin Pharmacol,2001,41(5):536-541.
9Ruddell WS,Dickinson RJ,Dixon MF,et al.Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse:comparison of hydrocortisone enemas and rectal hydrocortisone foam[J].Gut,1980,21(10):885-889.
10Marteau P,Probert CS,Lindgren S,et al.Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis:a randomised,double blind,placebo controlled study[J].Gut,2005,54(7):960-965.
